CNS Pharmaceuticals, Inc. stock is up 5.42% since 30 days ago. The next earnings date is Apr 1, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 4 February’s closed higher than January.
CNS Pharmaceuticals, Inc. engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials.
Unlock Exclusive Market Insights! Receive timely updates on market developments. Sign up & stay informed!